1	Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19					
2	and patient recovery in a non-severe case of COVID-17					
5 1						
4						
5						
07						
/	Ironi Thevereion ^{1,2#} Thi IIO Newyor ^{3#} Mening Keysterlog ³ Inlice Drugs ⁴ Leon Celu ⁴					
0	Inalli Thevarajali γ , Thi field Nguyeli , Marlos Koulsakos, Julian Diuce, Leon Cary,					
9 10	Caronien E van de Sandt , Alaoxiao Jia , Suenen Micholson , Mike Catton , Deniamin Courie ^{1,2} Steven VC Tene ^{1,2,6} Sharen B Lewin ^{2,3,7} and					
10	Kathoring Kadzioraka ³ *					
11	Kallellie Keuzielska					
12						
13						
14	A (C*1) - 4'					
15	Aimations					
10	Wistorien Infections Discours Commiss The Devel Mellowment Harmitel at the Deter					
l / 10	Victorian infectious Diseases Service, The Royal Melbourne Hospital at the Peter					
18	2Debarts Department The University of Mellourne 3000, victoria, Australia.					
19	Donerty Department, The University of Melbourne at The Peter Donerty Institute for					
20	³ D the formation of the second seco					
21	Department of Microbiology and Immunology, The University of Melbourne, at the					
22	Peter Donerty Institute for Infection and Immunity, Parkville 3010, Victoria,					
23	Australia.					
24	Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital					
25	at The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria,					
26	Australia.					
27	Department of Hematopolesis, Sanquin Research and Landsteiner Laboratory,					
28	Amsterdam UNIC, University of Amsterdam, 1066CX Amsterdam, Netherlands					
29	Menzies School of Health Research, Charles Darwin University, Darwin, Australia.					
3U 21	Department of Infectious Diseases, Alfred Hospital and Monash University,					
31	Melbourne, 3010, Victoria, Australia					
32						
33 24	*Correspondence: <u>kkedz(a)unimeto.edu.au</u> ; autnors contributed equally.					
34 25						
30						
30						
3/						
20 20	D erensing 4 ⁱ 4 as COVID 10 and cellular immunity					
39 10	Kuming une: COVID-19 and centular infinunity					
40 41						
41 42						
42 42						
43 11						
44						

45 We report the kinetics of the immune response in relation to clinical and 46 virological features of a patient with mild-to-moderate coronavirus disease-19 (COVID-19) requiring hospitalisation. Increased antibody-secreting cells, 47 48 follicular T-helper cells, activated CD4⁺ and CD8⁺ T-cells and IgM/IgG SARS-49 CoV-2-binding antibodies were detected in blood, prior to symptomatic 50 recovery. These immunological changes persisted for at least 7 days following 51 full resolution of symptoms, indicating substantial anti-viral immunity in this 52 non-severe COVID-19.

- 53
- 54

On 30/01/2020, a 47-year old woman from Wuhan, Hubei province, China presented 55 56 to an emergency department in Melbourne, Australia. Her symptoms commenced 4 57 days earlier with lethargy, sore throat, dry cough, pleuritic chest pain, mild dyspnoea 58 and subjective fevers (Fig.1a). She had travelled 11 days prior to presentation from 59 Wuhan via Guangzhou to Australia. She had no contact with the Huanan seafood 60 market or known COVID-19 cases. She was otherwise healthy, non-smoker, taking 61 no medications. Clinical examination revealed a temperature of 38.5°C, pulse rate 120 62 beats/minute, blood pressure 140/80 mmHg, respiratory rate 22 breaths/minute, and oxygen saturation 98%, while breathing ambient air. Lung auscultation revealed 63 bibasal rhonchi. At presentation day (d) 4, SARS-CoV-2 was detected by real-time 64 65 reverse transcriptase polymerase-chain-reaction (rRT-PCR) from a nasopharyngeal swab specimen. SARS-CoV-2 was again detected at d5-6 from nasopharyneal. 66 sputum and faecal samples, but was undetectable from d7 (Fg.1a). Blood C-reactive 67 protein was elevated at 83.2, with normal lymphocyte counts $(4.3 \times 10^9 / L \text{ [range 4.0-})$ 68 69 12.0×10^9 /L]) and normal neutrophil counts (6.3×10^9 /L [range $2.0-8.0 \times 10^9$ /L]). No other respiratory pathogens were detected. Her management was intravenous fluid 70 71 rehydration without supplemental oxygenation. No antibiotics, steroids or antiviral 72 agents were administered. Chest radiography demonstrated bibasal infiltrates at d5, 73 which cleared on d10 (Fig.1b), and she was discharged to home isolation on d11. 74 Symptoms resolved completely by d13 and she remained well at d20 post-onset of 75 symptoms. Progressive increase in plasma COVID-19-binding IgM/IgG antibodies, 76 from d7 until d20 was observed (Fig.1c).

77

78 There are currently no data defining immune responses leading to viral clearance and 79 clinical resolution of COVID-19. We addressed this knowledge gap by analysing the 80 breadth of immune responses in blood prior to patient recovery. As antibody-secreting cells (ASCs) are key for the rapid production of antibodies following viral Ebola 81 infection^{1,2}, influenza virus infection and vaccination^{2,3}; and activated circulating 82 follicular T helper (cTfhs) are concomitantly induced following influenza 83 84 vaccination³, we first determined the frequency of CD3⁻CD19⁺CD27^{hi}CD38^{hi} ASCs 85 and $CD4^{+}CXCR5^{+}ICOS^{+}PD1^{+}$ cTfh responses at 3 days prior to symptomatic 86 recovery. ASCs appeared in blood at the time of viral clearance at d7 (1.48%) and 87 peaked on d8 (6.91%). Emergence of cTfhs occurred concurrently in blood at d7 88 (1.98%), with the frequency increasing on d8 (3.25%) and d9 (4.46%) (Fig.2a). The 89 peak of both ASCs and cTfhs was markedly higher in the COVID-19 patient than the 90 baseline controls levels in healthy (average±SD: 0.61±0.40% and 91 $1.83\pm0.77\%$, respectively, n=5). Both ASCs and cTfhs were still prominently present 92 at convalescence (d20) (4.54% and 7.14%, respectively; Fig.2a). Our study provides 93 evidence on the recruitment of both ASCs and cTfhs in patient's blood whilst still

94 unwell and 3 days prior to resolution of symptoms, indicating their importance in 95 anti-viral immunity towards SARS-CoV-2.

96

97 Since co-expression of CD38 and HLA-DR is well defined as the key phenotype of 98 CD8⁺ T-cell activation towards viral infections, we analyzed activation of CD8⁺ T-99 cells by CD38/HLA-DR co-expression. In accordance with previous reports on Ebola 100 and influenza^{1,4}, CD38⁺HLA-DR⁺ co-expression on CD8⁺ T-cells rapidly increased 101 from d7 (3.57%) to d8 (5.32%) and d9 (11.8%), with a decrease at d20 (7.05%)102 (Fig.2b). Furthermore, the frequency of CD38⁺HLA-DR⁺ co-expression on CD8⁺ T-103 cells in this patient was markedly higher than on CD8⁺ T-cells in healthy 104 individuals (1.47±0.50%, n=5). Similarly, CD38⁺HLA-DR⁺ co-expression increased 105 on CD4⁺ T-cells between d7 (0.55%) and d9 (3.33%) in the patient, compared to 106 healthy donors $(0.63\pm0.28\%, n=5)$, although at lower levels than CD8⁺ T-cells. 107 CD38⁺HLA-DR⁺ T cells, especially within CD8⁺ T-cells, produced higher amounts 108 of granzymes A/B and perform (\sim 34-54% higher) than their parent (CD8⁺ or CD4⁺ 109 populations, Fig.2b). Thus, the emergence and rapid increase in activated 110 CD38⁺HLA-DR⁺ T-cells, especially CD8⁺ T-cells, at d7-9 preceded resolution of 111 symptoms.

112

We also analysed $CD16^+CD14^+$ monocytes, related to immunopathology, and activated HLA-DR⁺CD3⁻CD56⁺NK cells (**Fig.2c**). We detected reduced frequencies of CD16⁺CD14⁺ monocytes in peripheral blood at d7-9 (1.29%, 0.43%, 1.47%, respectively), compared to healthy controls (9.03±4.39%, n=5). This might indicate efflux of CD16⁺CD14⁺ monocytes from blood to the site of infection, which remained low at d20 (2.24%). Low levels of activated HLA-DR⁺CD3⁻CD56⁺NK cells were found in both the COVID-19 patient and healthy controls.

120

121 As high levels of pro-inflammatory cytokines/chemokines are predictive of severe 122 clinical outcomes for influenza⁵, seventeen pro-inflammatory cytokines/chemokines 123 were quantified in patient's plasma. We found low levels of monocyte 124 chemoattractant protein-1 (MCP-1; CCL2), important for the recruitment of 125 monocytes, T-cells and dendritic cells to the site of infection (Fig.2d). However, these 126 MCP-1 levels were similar to healthy donors $(22.15\pm13.81, n=5)$, patients infected 127 with influenza A (IAV) and influenza B viruses (IBV) at d7-9 (33.85±30.12, n=5) and 128 a patient with a known human coronavirus infection HCoV-229e (hCoV, 40.56). 129 Substantial levels of RANTES (CCL5), involved in homing and migration of 130 activated T-cells that express CCR5, were also detected in COVID-19 plasma but 131 these were comparable to healthy donors (p=0.412), IAV/IBV-infected patients 132 (p=0.310) and a hCoV-patient. Thus, in contrast to severe avian H7N9 disease with 133 highly elevated IL-6 and IL-8, and intermediate IL-10, MIP-1 β , IFN- γ^{5} , minimal pro-134 inflammatory cytokines/chemokines were found in this patient with CoVID-19, even 135 while symptomatic at d7-9.

136

Given that interferon-induced transmembrane protein-3 (IFITM3) single nucleotide polymorphism (SNP)-rs12252-C/C was linked to severe influenza^{5,6}, we analysed the IFITM3- rs12252 SNP in this patient with COVID-19. Interestingly, the patient had the 'risk' IFITM3-rs12252-C/C variant (**Fig.2e**), associated with clinical compromise for 2009-pH1N1⁶ and severe/fatal avian H7N9 disease⁵. As the relative prevalence of IFITM3-rs12252-C/C risk variant in a healthy Chinese population is 26.5% (data from 1,000 genome project)⁵, further investigations of the IFITM3-rs12252-C/C allele

144 in larger cohorts of patients with COVID-19 and its correlation with disease severity

- is worth pursuing.
- 146

147 Collectively, our study provides novel contributions to the understanding of the 148 breadth of the immune response during a non-severe case of COVID-19. This patient 149 did not experience complications of respiratory failure, acute respiratory distress 150 syndrome, did not require supplemental oxygenation and was discharged within a 151 week of hospitalization, consistent with non-severe but clearly symptomatic disease. 152 We provide evidence on the recruitment of immune populations (antibody-secreting B 153 cells, follicular T-cells, activated CD4⁺ and CD8⁺ T-cells), together with IgM-IgG 154 SARS-CoV-2-binding antibodies, in patient's blood prior to resolution of clinical 155 symptoms. We propose that these immune parameters should be characterised in 156 larger cohorts of patients with COVID-19 with different disease severity to 157 understand whether they could be used to predict disease outcome and to evaluate 158 new interventions to minimise severity and/or to inform protective vaccine 159 candidates. Furthermore, our study indicates that robust multi-factorial immune 160 responses can be elicited towards the newly-emerged SARS-CoV-2, and similar to the 161 avian H7N9 disease', early adaptive immune responses might correlate with better 162 clinical outcomes.

- 163
- 164

165 **References**

166 1. McElroy, A.K. *et al. Proc Natl Acad Sci USA* **112**, 4719-4724 (2015).

- 167 2. Ellebedy, A.H. et al. Nat Immunol 17, 1226-1234 (2016).
- 168 3. Koutsakos, M. et al. Sci Transl Med 10 (2018).
- 169 4. Wang, Z. et al. Nat Commun 9, 824 (2018).
- 170 5. Wang, Z. et al. Proc Natl Acad Sci USA 111, 769-774 (2014).
- 171 6. Everitt, A.R. et al. 484, 519-523 (2012).
- 172 7. Wang, Z. *Nat Commun* **6:** 6833 (2015).
- 173
- 174

175 Fig.1. Time course of clinical presentation and detection of SARS-CoV-2 in a 176 range of clinical specimens and antibodies to SARS-CoV2 in blood. (a) Timeline 177 of COVID-19; detection of SARS-CoV-2 virus in sputum, nasopharyngeal aspirates, 178 faeces but not urine, rectal swab and whole blood. SARS-CoV-2 was quantified by 179 real-time RT-PCR and the cycle threshold (Ct) is shown for each of the specimen. An 180 increase in Ct value is consistent with a decrease in viral load. The assay limit of 181 detection (LOD) threshold is Ct=45. Open circles: undetectable SARS-CoV-2; (b) 182 Radiological improvement from admission to discharge from hospital. 183 Anteroposterior chest radiographs on d5 (day of admission) and d10 following onset 184 of symptoms; (c, d) Immunofluorescence antibody staining for the detection of IgG 185 and IgM bound to SARS-CoV-2-infected vero cells using plasma (diluted 1:20) 186 collected at d7-9 and d20 following onset of symptoms.

187

Fig.2. Emergence of immune responses during non-severe symptomatic COVID19. Frequencies of (a) CD27^{hi}CD38^{hi} antibody-secreting cells (ASC; plasmablasts, gated on CD3⁻CD19⁺ lymphocytes) and activated ICOS⁺PD1⁺ follicular T helper
(Tfh) cells (gated on CD4⁺CXCR5⁺ lymphocytes); (b) activated CD38⁺HLA-DR⁺
CD8⁺ and CD4⁺ T-cells; (c) lineage⁻CD14⁺CD16⁺ monocytes and activated HLA-DR⁺
NK cells (gated on CD3⁻CD14⁻CD56⁺ cells) detected by flow cytometry for blood

collected at d7-d9 and d20 following onset of symptoms and in healthy donors (median with IQ range); (b) Histograms and line graphs of granzymes A/B/K/M and perforin (Prf) staining of parent CD8⁺ or CD4⁺ T cells and activated CD38⁺HLA-DR⁺CD8⁺/CD4⁺ T-cells are shown (bottom panels). (d) Plasma levels of proinflammatory cytokines/chemokines in COVID-19 patient at d7-9, healthy individuals (n=5, mean±SEM), patient with HCoV-229e and influenza-infected patients (n=5). (e)

- 200 'risk' IFITM3-rs12252 genotyping for the COVID-19 patient.
- 201 202

203 Acknowledgments

204 The authors thank Prof Cameron Simmons for supporting the development of 205 SETREP-ID, all the SETREP-ID investigators for their support and Australian 206 Partnership for Preparedness Research for Infectious Disease Emergencies 207 (APPRISE) for ongoing funding of SETREP-ID. We thank Dr Louise Rowntree for 208 technical assistance. This work was funded by the Australian National Health and 209 Medical Research Council (NHMRC) Investigator Grant to KK (#1173871). CES has 210 received funding from the European Union's Horizon 2020 research and innovation 211 programme under the Marie Skłodowska-Curie grant agreement No 792532 and 212 University of Melbourne McKenzie Fellowship laboratory support. KK is supported 213 by a NHMRC Senior Research Fellowship Level B (#1102792) and SRL is supported 214 by an NHMRC Practitioner Fellowship and an NHMRC program grant. SYCT is 215 supported by a NHMRC Career Development Fellowship (#1145033). XJ is 216 supported by China Scholarship Council-University of Melbourne joint Scholarship. 217 The authors wish to acknowledge our public health partners, and VIDRL's major 218 funder, the Victorian Department of Health and Human Services without whom this 219 work would not have been possible, and the clinical and laboratory staff involved in 220 the care of this patient.

- 220
- 222
- 223 224

225

Online content

226 Author contribution

IT, THON, MK, CES, LC, SN, XJ, JD, MK, BC, SYT, SRL, KK formulated ideas,
designed the study and experiments; THON, MK, CES, LC, SN, XJ, JD performed
experiments; THON, MK, LC, SN, JD analysed the experimental data, KK, IT,
THON, SYT, BC, SRL wrote the manuscript. All authors reviewed the manuscript.

231

232 **Competing interests**

The authors declare no conflict of interest. SRL's institution has received funding for investigator initiated research grants from Gilead Sciences, Merck, Viiv Healthcare and Leidos. She has received honoraria for participation in advisory boards and educational activities for Gilead Sciences, Merck, Viiv Healthcare and Abbvie.

237

238 Methods

239 Study design

The patient was enrolled through the Sentinel Travelers Research Preparedness
 Platform for Emerging Infectious Diseases novel coronavirus substudy (SETREP-ID
 coV). Sputum, nasopharyngeal aspirates, urine and faecal specimens as well as whole

blood in sodium heparin tubes were collected over the duration of illness and 9 days 243 244 post discharge for quantitative virology, immunology and assessment of host gene 245 factors. Human experimental work was conducted according to the Declaration of 246 Helsinki Principles and according to the Australian National Health and Medical 247 Research Council Code of Practice. Participants provided written informed consent 248 prior to the study. The study was approved by the Royal Melbourne Hospital (HREC 249 Reference number: HREC/17/MH/53 and HREC/15/MonH/64/2016.196) and 250 University of Melbourne (ID #1442952.1 and #1443389.4) Human Research Ethics 251 Committees.

252

253 Generation of SARS-CoV-2 cDNA

RNA was extracted from 200µL from patient's swabs (nasopharyngeal, rectal, throat
in VTM), sputum, urine, faeces and whole-blood samples using the QIAamp 96 Virus
QIAcube HT Kit (Qiagen, Hilden, Germany). Reverse transcription was performed
using the BioLine SensiFAST cDNA kit (Bioline, London, United Kingdom). Total
reaction mixture of 20µl contained 10µL of the RNA extract, 4µl of 5x TransAmp
buffer, 1µl of Reverse Transcriptase and 5µl of Nuclease free water. Reactions were
incubated at 25°C for 10 min, 42°C for 15 min, 85°C for 5 min.

261

262 Nested SARS-CoV-2 RT-PCR and Sanger sequencing

263 A PCR mixture containing 2µl cDNA, 1.6µl of 25 mM MgCl₂, 4µl of 10x Qiagen Taq 264 Buffer, 0.4µl of 20mM dNTPs, 0.3µl of Taq polymerase (Qiagen, Hilden, Germany) 265 and 2µl of 10µM primer pools as described¹¹. The first round included the forward 266 (5'-GGKTGGGAYTAYCCKAARTG-3') reverse (5'and 267 GGKTGGGAYTAYCCKAARTG-3') primers. Cycling conditions were 94°C for 10 268 min, followed by 30 cycles of 94°C for 30s, 48°C for 30s and 72°C for 40s, with a 269 final extension of 72°C for 10 min. PCR product (2µl) was used in the second round 270 PCR reaction which included the forward (5'-GGTTGGGACTATCCTAAGTGTGA-271 3') and reverse (5'-CCATCATCAGATAGAATCATCAT-3') primers. Cycling 272 conditions were 94°C for 10min, followed by 40 cycles of 94°C for 30s, 50°C for 30s 273 and 72°C for 40s, with a final extension of 72°C for 10 min. PCR products had an 274 expected size of approximately 440bp on a 2% agarose gel. The PCR products were 275 purified using ExoSAP-IT (Affymetrix, Santa Clara, CA, USA) and sequenced using 276 an Applied Biosystems SeqStudio Genetic Analyzer (Life Technologies, Carlsbad, 277 CA, USA) using Big Dye Terminator 3.1 (Life Technologies, Carlsbad, CA, USA) 278 and Round 2 PCR primers above. SARS-CoV and 229e-CoV cDNA were used as 279 positive controls.

280

281 Detection of SARS-CoV-2 using TaqMan Real-time RT-PCR E-gene assay

282 TaqMan RT-PCR assay comprised of 2.5µl cDNA, 10µl Primer Design 283 PrecisonPLUS qPCR Master Mix 1µM Forward (5'-ACA GGT ACG TTA ATA GTT 284 AAT AGC GT -3'), 1µM Reverse (5'-ATA TTG CAG CAG TAC GCA CAC A-3') 285 primers and 0.2µM Probe (5'-FAM-ACA CTA GCC ATC CTT ACT GCG CTT CG-286 NFQ-3') targeting the Betacoronavirus E-gene¹. The real-time RT-PCR assay was 287 performed on an Applied Biosystems ABI 7500 Fast Real-time PCR machine 288 (Applied Biosystems, Foster City, CA, USA) with cycling conditions 95°C for 2min, 289 95°C for 5s, 60°C for 24s. SARS-CoV cDNA (Ct~30) was used as a positive control.

290

291 IFITM3 SNP analysis

PCR was performed on genomic DNA extracted from patient's granulocytes (using
QIAamp DNA Mini Kit, QIAGEN) to amplify the *exon 1* rs12252 region using
forward (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'CATACGCACCTTCACGGAGT-3') primers².

296

297 Cytokine analysis

Patient's plasma was diluted 1:4 before measuring cytokine levels (IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-1β, IFN-α, MIP-1α, MIP-1β, MCP-1, CD178/FasL, granzyme B, RANTES, TNF, IFN- γ) using the Human CBA Kit (BD Biosciences, San Jose, California, USA). For RANTES, sera/plasma was also diluted to 1:50. Healthy donors D6-D10 were of a mean age of 32 (range 22-55 years; 40% females).

304

305 Whole blood staining and flow cytometry

306 Fresh whole blood (200µl per stain) was used to measure $CD4^+CXCR5^+ICOS^+PD1^+$ 307 follicular T cells (Tfh) and CD3⁻CD19⁺CD27^{hi}CD38^{hi} antibody-secreting B cell (ASC; plasmablast) populations as described³ as well as activated HLA-308 309 DR⁺CD38⁺CD8⁺ and HLA-DR⁺CD38⁺CD4⁺ T cells, inflammatory CD14⁺CD16⁺ and 310 conventional CD14+ monocytes, activated HLA-DR⁺CD3⁻CD56⁺ NK cells, as per the 311 specific antibody panels (Supplementary Table 1; gating strategy is presented in 312 Supplementary Fig.1). After the whole blood was stained for 20 mins at room 313 temperature (RT) in the dark, samples were lysed with BD FACS Lysing solution, 314 washed and fixed with 1% PFA. Granzymes/perforin staining (patient d20) was 315 performed using the eBioscience Foxp3/Transcription Factor Staining Buffer Set after 316 the lysis step. All the samples were acquired on a LSRII Fortessa (BD). Flow 317 cytometry data were analyzed using FlowJo v10 software. Healthy donors D1-D5 318 were of a mean age of 35 (range 24-42 years, 40% females).

319

320 Detection of IgG and IgM antibodies in SARS-CoV-2 -infected vero cells

321 Immunofluorescence antibody tests for the detection of IgG and IgM were performed 322 using SARS-CoV-2-infected vero cells that had been washed with PBS and 323 methanol/acetone fixed onto glass slides. Ten μ L of a 1/20 dilution of patient plasma 324 in PBS from days 7, 8, 9 and 20 were incubated on separate wells for 30 mins at 325 37°C, then washed in PBS and further incubated with 10µL of FITC-conjugated goat 326 anti-human IgG and IgM (Euroimmun, Lübeck, Germany) before viewing on a 327 EUROStar III Plus fluorescent microscope (Euroimmun). Prior to detection of IgM 328 antibodies, samples were pre-treated with RF-SorboTech (Alere, Rűsselsheim, 329 Germany) to remove IgG antibodies and rheumatoid factors, which may cause false-330 negative and false-positive IgM results, respectively.

331

332 **Reference**

- 333 1. Corman, V.M. et al. Euroservaillance 25, doi: 10.2807/1560-
- 334 7917.ES.2020.25.3.2000045 (2020).
- 335 2. Clemens, E.B. et al. Immunol & Cell Biol 94, 367-377 (2016).
- 336 3. Koutsakos, M. et al. Sci Transl Med 10 (2018).
- 337
- 338
- 339
- 340 Data availability

341 The data that support the findings of this study are available from the corresponding

author upon request. Raw FACS data are shown in the manuscript.

343 344

345 Supplementary Table 1. Whole blood immunophenotyping and antibody panels 346 used in our immune assays.

347

Supplementary Figure 1. Flow cytometry gating strategy for immune cell
subsets. Gating panels are shown for (a) CD27^{hi}CD38^{hi} ASCs and activated
ICOS⁺PD1⁺ Tfh cells; (b) activated CD38⁺HLA-DR⁺ CD8⁺ and CD4⁺ T-cells,
activated HLA-DR⁺ NK cells and lineage⁻CD14⁺CD16⁺ monocytes; and (c)
granzymes (GZM) A/B/K/M and perforin expression on CD8⁺/CD4⁺ T-cells and
activated CD38⁺HLA-DR⁺ CD8⁺/CD4⁺ T-cells.

354



С

b Day 5

Day 10



	Neg	d7	d8	d9	d20
Anti-IgG	0	1+	2+	3+	3+
Anti-IgM	0	+/-	+/-	2+	3+

COVID-19 patient



Figure 1. Thevarajan et al



Figure 2. Thevarajan et al